Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
'Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,' said John T. Treace, Chairman, CEO and Founder of Treace. 'Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.'
Treace's patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@treace.net(904) 373-5940
Investors:Gilmartin GroupPhilip Trip Taylor IR@treace.net
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of Meghan Geary as the Company's Senior Vice President of Operations, effective immediately. With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory. "I'm excited to join MedX at such a pivotal stage of its journey," said Geary. "Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success." The Company's CEO, John Gevisser added: 'Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.' About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration ('FDA'), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: https// This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Yahoo
35 minutes ago
- Yahoo
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial
Merck & Co., Inc. (NYSE:MRK) is included in our list of the . A dose bottle of the medication is in the medical tech's hand On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The study revealed improved event-free survival, overall survival, and pathologic complete response rates compared to surgery alone. The improved outcome was a result of giving patients KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) medicines before and after surgery. The trial, carried out in collaboration with Pfizer and Astellas, marks the first systemic treatment that enhances survival rates in this patient group. Furthermore, no new side effects were observed. Operating through its Pharmaceutical and Animal Health segments, Merck & Co., Inc. (NYSE:MRK) leads as a healthcare company worldwide. It is included in our list of the most undervalued value stocks to buy. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None.
Business Wire
2 hours ago
- Business Wire
Corpay Cross-Border 成為 New Zealand Football 官方外匯合作夥伴
多倫多--(BUSINESS WIRE)--(美國商業資訊)-- Corpay, Inc.* (紐約證券交易所代碼：CPAY) 作為全球企業支付領域的領導者，欣然宣佈旗下 Corpay Cross-Border 業務已與 New Zealand Football 簽署協議，成為其官方外匯合作（FX）夥伴。 透過這項合作，New Zealand Football 將能運用 Corpay Cross-Border 的創新解決方案，協助降低日常營運中的外匯風險。此外，Corpay Cross-Border 屢獲殊榮的平台，亦將使其能夠透過單一入口管理全球支付。 「Corpay Cross-Border 謹此恭賀 New Zealand Football 及 All Whites 成功取得 2026 FIFA 世界盃的參賽資格。」Corpay Cross-Border Solutions 首席市場營銷官 Brad Loder 表示，「我們高度重視 Corpay 品牌的發展，以及在紐西蘭的企業支付及外匯風險管理業務。作為官方外匯合作夥伴，我們期待與 New Zealand Football 攜手備戰世界盃，並建立長期合作關係。」 「隨着我們機構的發展與成熟，需要持續檢視國際營運的方式。此次與大型金融機構的合作，顯示我們已經站在全球化的思維層面。」New Zealand Football 行政總裁 Andrew Pragnell 表示，「能夠在紐西蘭足球運動蓬勃發展的時刻與 Corpay 合作，實在令人振奮，因為這項運動正在紐西蘭的各個層面持續壯大。」 關於Corpay Corpay, Inc. (NYSE: CPAY)是一家全球性標準普爾500指數企業支付公司，致力於協助企業和消費者以簡單、可控的方式支付費用。Corpay的現代支付解決方案套件協助其客戶更好地管理與車輛相關的費用（如加油和停車）、旅行費用（如酒店預訂）和應付帳款（如向供應商付款），從而讓我們的客戶能夠節省時間並最終減少支出。Corpay Cross-Border是指由Corpay, Inc.擁有和經營的一組法律實體。 Corpay——讓付款變得簡單。如欲瞭解更多資訊，請造訪： 。 *本文中的「Corpay」主要指Corpay, Inc.的跨境業務部門： ；查看Corpay跨境業務部門旗下公司的完整列表，請造訪： 。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
